Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,249,000 | 2,669,000 | 2,143,000 | 2,801,000 | 2,225,000 |
| Receivables | 3,385,000 | 3,539,000 | 3,435,000 | 3,696,000 | 3,730,000 |
| Inventories | 4,051,000 | 4,109,000 | 4,118,000 | 3,833,000 | 3,859,000 |
| Other current assets | 572,000 | 543,000 | 552,000 | 559,000 | 594,000 |
| TOTAL | $11,425,000 | $12,088,000 | $11,501,000 | $12,051,000 | $11,453,000 |
| Non-Current Assets | |||||
| PPE Net | 5,622,000 | 5,712,000 | 5,751,000 | 5,739,000 | 5,568,000 |
| Intangibles | 22,410,000 | 22,856,000 | 23,763,000 | 23,903,000 | 24,826,000 |
| Other Non-Current Assets | 2,631,000 | 2,439,000 | 2,442,000 | 2,318,000 | 2,406,000 |
| TOTAL | $30,663,000 | $31,007,000 | $31,956,000 | $31,960,000 | $32,800,000 |
| Total Assets | $42,088,000 | $43,095,000 | $43,456,000 | $44,011,000 | $44,252,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,479,000 | 1,980,000 | 1,023,000 | 2,109,000 | 2,769,000 |
| Accounts payable and accrued liabilities | 2,280,000 | 2,508,000 | 2,381,000 | 1,887,000 | 1,635,000 |
| Accrued Expenses | 3,271,000 | 2,949,000 | 2,699,000 | 2,717,000 | 2,537,000 |
| Other current liabilities | 4,362,000 | 4,406,000 | 4,309,000 | 4,755,000 | 4,593,000 |
| TOTAL | $11,394,000 | $11,843,000 | $10,411,000 | $11,469,000 | $11,534,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 18,495,000 | 18,698,000 | 19,668,000 | 19,103,000 | 18,497,000 |
| Other Non-Current Liabilities | 4,134,000 | 4,346,000 | 4,247,000 | 4,326,000 | 4,197,000 |
| TOTAL | $23,181,000 | $23,543,000 | $24,432,000 | $23,945,000 | $23,200,000 |
| Total Liabilities | $34,576,000 | $35,387,000 | $34,844,000 | $35,413,000 | $34,734,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,120,971 | 1,120,650 | 1,120,406 | 1,110,900 | 1,110,645 |
| Common Shares | 57,000 | 57,000 | 57,000 | 57,000 | 57,000 |
| Retained earnings | -13,870,000 | -13,950,000 | -13,086,000 | -12,975,000 | -11,660,000 |
| Other shareholders' equity | -2,327,000 | -2,019,000 | -1,950,000 | -2,044,000 | -2,402,000 |
| TOTAL | $7,512,000 | $7,708,000 | $8,612,000 | $8,598,000 | $9,519,000 |
| Total Liabilities And Equity | $42,088,000 | $43,095,000 | $43,456,000 | $44,011,000 | $44,253,000 |